Atopic Dermatitis

Peter Lio, MD also explained why he considers it a bad day when he does not learn something new about this disease.

AB-101a is a new topical treatment being investigated for mild, moderate, and severe atopic dermatitis and its immune system component.

Peter Lio, MD, FAAD, discusses how body surface area of atopic dermatitis (AD) affects topical treatment options.

Shawn Kwatra, MD, offers important considerations for providers when utilizing topical therapies for atopic dermatitis (AD).

The TRuE-AD3 study met its primary endpoint of IGA-TS improvement from baseline at week 8.

Alphyn Biologics announced positive results from their Phase 2a trial of AB-101a will lead to a multinational Phase 2b trial soon.

Dupilumab self-injection has been available to patients in Japan since May 2019.

Examining the genes and signaling pathways of development of atopic dermatitis and tooth agenesis reveals possible link between the two diseases.

Findings indicate no rebound effect when participants discontinue dupilumab.

Pediatric patients with moderate to severe eczema demonstrated an increased risk of experiencing the food allergy.

Experts discuss the history and evolving landscape of topical steroids as therapy for atopic dermatitis (AD).

Peter Lio, MD, FAAD, and Shawn Kwatra, MD, discuss janus kinase (JAK) inhibitors and their recent use in the treatment of atopic dermatitis (AD).

The ongoing Canadian wildfires are causing poor air quality in the US, which will likely result in more patients seeking help for skin conditions.

Sanofi’s investigational anti-OX40-ligand monoclonal antibody showed statistically significant improvement in signs and symptoms of AD in adults.

Experts discuss the symptoms of atopic dermatitis (AD) and how disease severity may impact symptoms.

Shawn Kwatra, MD, and Peter Lio, MD, FAAD, discuss the burden of atopic dermatitis (AD) and how it may affect pediatric or adult patients.

A poster presented at the SDPA Annual Summer Dermatology Conference revealed the abrocitinib did not have a significant impact on adolescent immune responses to Tdap vaccination.

Four clinicians discuss the widening landscape of systemic therapies for patients with atopic dermatitis.

Four dermatologists from across the country discuss the widened armamentarium of AD treatments in a recent Around the Practice series.

Expert dermatologists review a final case about a 32-year-old male with AD, highlighting systemic therapy as first-line treatment.

Elizabeth Swanson, MD, shares pearls on how to communicate with AD patients who are uncertain about treatment through self-administered injection.

The current dermatology pipeline includes a wide range of medication classes, from Janus kinase (JAK) inhibitors to tumor necrosis factor inhibitors, to phototherapeutics

The new technique analyzes RNA from infant sebum samples.

Experts in dermatology review recommendations for systemic therapies and JAK inhibitors in the management of AD and other factors that guide treatment selection.

Jonathan I Silverberg, MD, PhD, MPH; Elizabeth Swanson, MD; Brad Glick, DO, MPH, FAOCD; and Andrew Blauvelt, MD, MBA, discuss their initial impressions of an adolescent patient with AD, focusing on systemic therapy.